Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
-2.05 (-2.31%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Blueprint Medicines Revenue

In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth. Revenue in the quarter ending December 31, 2023 was $71.96M with 85.55% year-over-year growth.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
5.32B USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Dec 31, 2023249.38M45.34M22.22%
Dec 31, 2022204.04M23.96M13.30%
Dec 31, 2021180.08M-613.66M-77.31%
Dec 31, 2020793.74M727.22M1,093.37%
Dec 31, 201966.51M21.99M49.39%
Dec 31, 201844.52M23.10M107.79%
Dec 31, 201721.43M-6.35M-22.85%
Dec 31, 201627.77M16.37M143.61%
Dec 31, 201511.40M--
Dec 31, 20140--
Dec 31, 20130--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Grifols 6.45B
Option Care Health 4.30B
Bausch + Lomb 4.15B
R1 RCM 2.25B
Halozyme Therapeutics 829.25M
Ionis Pharmaceuticals 787.65M
Apellis Pharmaceuticals 396.59M
Revenue Rankings